

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: PATI92360

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
Biogen Idec International Holding Ltd.	08/19/2013
<b>RECEIVING PARTY DATA</b>	
<b>Company Name:</b>	Biogen Idec MA Inc.
<b>Street Address:</b>	14 Cambridge Center
<b>City:</b>	Cambridge
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02142
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17191589
<b>Application Number:</b>	15914980
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(415)954-0200
<b>Email:</b>	IP-SQUIRE@SQUIREPB.COM
<b>Correspondent Name:</b>	Todd Lorenz
<b>Address Line 1:</b>	555 California St
<b>Address Line 2:</b>	Suite 550
<b>Address Line 4:</b>	San Francisco, CALIFORNIA 94104
<b>NAME OF SUBMITTER:</b>	Kelly Quintana
<b>SIGNATURE:</b>	Kelly Quintana
<b>DATE SIGNED:</b>	03/15/2024
<b>Total Attachments: 70</b>	
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page1.tif	
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page2.tif	
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page3.tif	
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page4.tif	
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page5.tif	

[illegible]

source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page54.tif  
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page55.tif  
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page56.tif  
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page57.tif  
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page58.tif  
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page59.tif  
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page60.tif  
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page61.tif  
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page62.tif  
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page63.tif  
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page64.tif  
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page65.tif  
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page66.tif  
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page67.tif  
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page68.tif  
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page69.tif  
source=P1072US008 BIOGEN IDEC INTL to BIOGEN IDEC MA INC#page70.tif

**CONFIRMATION OF ASSIGNMENT AND ASSUMPTION  
(PATENT ASSETS)**

This CONFIRMATION OF ASSIGNMENT AND ASSUMPTION AGREEMENT, (this "Confirmation"), is made and entered into by and between Biogen Idec International Holding Ltd., a corporation of Bermuda having a place of business at Canon's Court, 22 Victoria Street, Hamilton HM EX, Bermuda, ("Bermuda") and Biogen Idec MA Inc., a corporation of Massachusetts having a place of business at 14 Cambridge Center, Cambridge, Massachusetts 02142, ("BIMA"). Bermuda and BIMA are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

WHEREAS, Bermuda is party to that certain Asset Purchase Agreement, among Bermuda, Elan Pharma International Limited and Elan Pharmaceuticals, Inc. dated as of February 5, 2013 (the "Asset Purchase Agreement");

WHEREAS, Bermuda and BIMA are parties to that certain Assignment and Assumption Agreement, dated as of April 2, 2013 (the "Assignment and Assumption Agreement");

WHEREAS, pursuant to the Asset Purchase Agreement Bermuda acquired the Transferred Assets (other than the Transferred Inventory) and assumed the Assumed Liabilities;

WHEREAS, the rights and resources acquired through the Asset Purchase Agreement have been added to the Intangible Development Activity as defined under the Tysabri R&D Cost Sharing Agreement between the Parties (as such agreement may be amended and restated from time to time) (the "CSA Agreement"), and the fair market value consideration set forth in the Assignment and Assumption Agreement was intended to satisfy BIMA's obligation to make PCT Payments as specified and as defined in such CSA Agreement;

WHEREAS, as set forth in the Assignment and Assumption Agreement, the Parties wish for purposes of administrative convenience and the defense of intangible property rights that BIMA acquire and hold legal title to, inter alia, all Patent Assets as defined below, subject to Bermuda's retention of beneficial ownership of all rights to the Ex-U.S. Patent Assets, as defined below, through a perpetual and exclusive royalty free license of such rights;

WHEREAS, pursuant to the terms of the Assignment and Assumption Agreement, the Parties intend (i) as described above, for legal title of the Patent Assets to be transferred and held by BIMA or a U.S. affiliate, (ii) for Bermuda to transfer to BIMA, and BIMA to receive and hold beneficial ownership of all U.S. Patent Assets, as defined below, and (iii) for Bermuda to retain beneficial ownership of all rights in the Ex-U.S. Patent Assets;

WHEREAS, pursuant to the terms of the Assignment and Assumption Agreement, the Parties wish to assign, transfer and convey to BIMA, and BIMA desires to assume and accept, all Assumed Liabilities to the extent related to the U.S. Patent Assets, (collectively, the "Assumed U.S. Patent Liabilities");

NOW, THEREFORE, in consideration of the covenants and agreements contained herein and in the Assignment and Assumption Agreement, and other good and valuable consideration, including as set forth in the Assignment and Assumption Agreement, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the Parties agree as follows:

1. Definitions.

- a. Capitalized terms used herein but not defined herein have the respective meanings ascribed to them in the Asset Purchase Agreement and the Assignment and Assumption Agreement, and the rules of usage set forth therein shall apply hereto.
- b. "Patent Assets" shall mean U.S. Patent Assets and Ex-U.S. Patent Assets;
- c. "U.S. Patent Assets" shall mean:
  - i. Each of the patents and patent applications set forth in Schedule A, annexed hereto and made a part hereof;
  - ii. Any and all United States patents and patent applications that claim the benefit of the patents and patent applications set forth in Schedule A, including any and all United States utility patents and patent applications, including non-provisional, continuing (continuation, continuation-in-part or divisional), reissue, and reexamination applications, utility models, and design registrations;
  - iii. Any and all inventions described in each of the patents and patent applications set forth in Schedule A, and in all forms of intellectual and industrial property protection derivable therefrom, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patents and patent applications, including without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor, and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the United States, as may be applicable;
- d. "Ex-U.S. Patent Assets" shall mean:
  - i. Each of the patents and patent applications set forth in Schedule B, annexed hereto and made a part hereof;
  - ii. Any and all non-United States patents and patent applications that claim the benefit of the patents and patent applications set forth in Schedule B, including any and all non-United States utility patents and patent applications, including non-provisional, continuing (continuation, continuation-in-part or divisional), reissue, and reexamination applications, utility models, and design registrations;
  - iii. Any and all inventions described in each of the patents and patent applications set forth in Schedule B, and in all forms of intellectual and industrial property protection derivable therefrom, and that are derivable from any and all continuing applications, reissues,

extensions, renewals and reexaminations of such patents and patent applications, including without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor, and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable.

2. Assignment of Title. Bermuda hereby confirms that it has assigned, transferred and conveyed to BIMA all of its legal title to the Patent Assets, subject to Bermuda's retention of the perpetual and exclusive royalty-free license to the Ex-U.S. Patent Assets as specified in Section 5 of this Confirmation.

3. Assignment of Rights and Beneficial Ownership of the U.S. Patent Assets. Bermuda hereby confirms that it has assigned, transferred and conveyed to BIMA all of its right, title and interest in, and to the U.S. Patent Assets, including the right to sue for past infringement and to collect for all past, present and future damages.

4. Acceptance and Assumption of Rights and Liabilities. BIMA hereby (A) confirms its Acceptance of the assignment, transfer and conveyance of (i) title to the Patent Assets subject to Bermuda's retention of the perpetual and exclusive royalty free license of all rights to the Ex-U.S. Patent Assets specified in Section 5 of this Confirmation, (ii) the U.S. Patent Assets and (B) confirms its assumption of the Assumed U.S. Patent Liabilities, and its agreement to timely pay, honor, discharge and perform or otherwise satisfy when due, or cause to be timely paid, honored, discharged, performed or otherwise satisfied when due, all of the Assumed U.S. Patent Liabilities.

5. Grant of License. The assignment of legal title to the Patent Assets described in Section 2 of this Confirmation is subject to BIMA's grant and Bermuda's retention of an exclusive, perpetual, irrevocable royalty-free, fully paid up license, with the right to grant and authorize sublicenses, to the Ex-U.S. Patent Assets including, without limitation (i) to manufacture (or have manufactured) Products (as defined in the CSA Agreement) in all countries outside the United States ("the Ex-U.S. territory"), (ii) to use, license, sell, offer for sale, or import the Products in or into the Ex-U.S. Territory, (iii) to use, reproduce, distribute, perform or display the Products in the Ex-U.S. Territory, (iv) to make (or have made) modifications, enhancements or further developments to the Products under the IDA (as defined in the CSA Agreement) in the Ex-U.S. Territory and (v) to otherwise use and exploit the Ex-U.S. Patent Assets.

6. Further Assurances. Each Party hereby covenants and agrees that, without further consideration, it shall execute such documents and take such further action as any other Party may reasonably request in order to effectuate the assignments, transfers, conveyances and assumptions set forth herein.

7. Effectiveness. This Confirmation shall be effective as of April 2, 2013, immediately after the Closing. To the extent local law prohibits the assignment from Bermuda to BIMA of any specific patents or patent applications among the Patent Assets from being effective as of April 2, 2013, the assignment of said specific patents or patent applications shall be effective as of the first date on which such assignment is permitted under local law.

8. Governing Law. This Confirmation shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without giving effect to principles of conflict of laws.

9. Successors and Assigns; Limitation on Rights of Others. The terms of this Confirmation shall be binding upon, and inure to the benefit of, the Parties and their respective legal representatives, successors and assigns. Nothing in this Confirmation, whether express or implied, shall be construed to give any Person (other than the Parties hereto and their respective successors and assigns) any legal or equitable right, remedy or claim under, or in respect of, this Confirmation or any covenants, conditions or provisions contained herein, as a third party beneficiary or otherwise.

10. Counterparts. This Confirmation may be executed in any number of counterparts, each of which shall be deemed as original, but all of which together shall constitute one instrument.

*[Signature Pages Follow]*



SIGNED, on behalf of the said Bermuda,

BIOGEN IDEC INTERNATIONAL HOLDING LTD.

By: 

Name: M. T. AMISSAH

Title: DIRECTOR


Date: 19<sup>th</sup> AUGUST 2013

Before me this 19<sup>th</sup> day of AUGUST, 2013, personally appeared M. T. AMISSAH known to me to be the person whose name is subscribed to the foregoing Assignment, proved to me through satisfactory evidence of identification in the form of PASSPORT, and acknowledged that he/she executed the same as his/her free act and deed for the purposes therein contained.

  
Notary Public

My Commission Expires: 19 AUGUST 2013

Here]



Jennifer S. Eve  
Notary Public  
Canon's Court  
22 Victoria Street  
P.O. Box HM 1179  
Hamilton HM EX  
Bermuda  
Date: 19 AUGUST 2013



SIGNED, on behalf of the said BIMA,

BIOGEN IDEC MA INC.

By: Lynne Sullivan  
Name: Lynne Sullivan  
Title: VP Tax  
Date: 8-19-13


Before me this 19 day of August, 2013, personally  
appeared Lynne Sullivan known to me to be the person whose name is subscribed to the foregoing  
Assignment, proved to me through satisfactory evidence of identification in the form of  
Massachusetts Driver's Licence, and acknowledged that he/she executed the same as  
his/her free act and deed for the purposes therein contained.

A. Williams

Notary Public

My Commission Expires:

[Notary's Seal Here]



Signature Page to Confirmation of Assignment and Assumption

**PATENT**  
**REEL: 066800 FRAME: 0357**

Schedule A

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0002-PR	61/406,358	Oct-25-2010		METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMadCAM LEVELS
ELN-0002-PR1	61/406,365	Oct-25-2010		METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMadCAM LEVELS
ELN-0002-US	13/881,520	Oct-24-2011		METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IS sVCAM AND/OR sMadCAM LEVELS

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0003-US	11/711,628	Feb-28-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0003-US-D1	12/757,305	Apr-09-2010		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0004-US	11/713,000	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-US-C1	13/425,058	Mar-20-2012		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0007-US	07/413,274	Sep-27-1989		BLOOD-BRAIN BARRIER MODEL
ELN-0007-US-C1	08/402,962	Mar-10-1995		COMPOSITIONS AND METHODS FOR MODULATING LEUKOCYTE ADHESION TO BRAIN ENDOTHELIAL CELLS
ELN-0007-US-C2	08/457,847	Jun-01-1995	6,033,665	COMPOSITIONS AND METHODS FOR MODULATING LEUKOCYTE ADHESION TO BRAIN ENDOTHELIAL CELLS
ELN-0007-US-CIP1	07/577,650	Sep-04-1990	5,260,210	BLOOD-BRAIN BARRIER MODEL
ELN-0007-US-CIP2	07/871,223	Apr-17-1992		COMPOSITIONS AND METHODS FOR MODULATING LEUKOCYTE ADHESION TO BRAIN ENDOTHELIAL CELLS

Schedule A

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0008-US	08/186,269	Jan-25-1994		HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-US-CIP1	08/561,521	Nov-21-1995	5,840,299	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-US02	09/155,739	Nov-21-1996		THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
ELN-0008-US-C1	11/006,808	Dec-08-2004	7,435,802	HUMANIZED ANTI-VLA4 IMMUNOGLOBINS
ELN-0008-US-C2	12/175,116	Jul-17-2008	8,246,958	METHODS OF INHIBITING ALPHA-4 DEPENDENT INTERACTIONS WITH VCAM-1 WITH ANTI-VLA-4 ANTIBODIES
ELN-0008-US-C3	13/540,462	Jul-02-2012		THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0009-PR1	60/360,134	Feb-25-2002		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-PR2	60/374,501	Apr-23-2002		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-US	10/372,111	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-US-D1	11/540,640	Oct-02-2006	7,807,167	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-US-D2	12/846,350	Jul-29-2010		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0010-PR1	60/442,171	Jan-24-2003		REVERSAL OF INFLAMMATORY RESPONSE BY INHIBITION OF ALPHA-4 INTEGRIN TO INHIBIT DEMYELINATION
ELN-0010-PR2	60/500,316	Sep-05-2003		REVERSAL OF INFLAMMATORY RESPONSE BY INHIBITION OF ALPHA-4 INTEGRIN TO INHIBIT DEMYELINATION AND REVERSE PARALYSIS
ELN-0010-US1	10/763,424	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-US2	10/763,539	Jan-26-2004	7,576,101	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS

Schedule A

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0011-PR	60/445,818	Feb-10-2003		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-PR1	60/929,133	Jun-14-2007		LYOPHILIZED IMMUNOGLOBULIN FORMULATION AND METHDS OF PREPARATION
ELN-0011-US	10/773,406	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-US-C2	12/572,978	Oct-02-2009	8,349,321	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-US2	13/605,590	Sep-06-2012		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-US3	13/676,866	Nov-14-2012		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0012-PR	60/541,946	Feb-06-2004		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-US	11/049,365	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0013-PR	60/558,120	Apr-01-2004		STERIOD SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-PR1	60/558,121	Apr-01-2004		STERIOD SPARING AGENTS AND METHODS OF USING SAME
ELN-0013-US1	11/095,822	Apr-01-2005		STERIOD SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-US2	11/096,074	Apr-01-2005		STERIOD SPARING AGENTS AND METHODS OF USING THE SAME

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent Number	Grant Date
342837-1451	CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	09/987619	11/15/2001	6900179	5/31/2005
342837-1453	CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	10/316205	12/11/2002	7320960	1/22/2008
342837-1454	Anti-Inflammatory Compositions and Method	United States of America	09/127364	7/31/1998	6939855	9/6/2005

Schedule A

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1450	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	09/126958	7/31/1998	6489300	12/3/2002
342837-1487	CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	11/128732	5/13/2005	7229970	6/12/2007
342837-1452	CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	09/987900	11/16/2001	6525026	2/25/2003
342837-1488	Anti-Inflammatory Compositions and Methods	United States of America	11/147601	6/7/2005		
342837-1450X	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	60/112020	7/31/1997		
342837-1451/X/X	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	08/904424	7/31/1997		
342837-1451X	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	60/054453	8/1/1997		
342837-1550	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	09/489377	1/21/2000	6492372	12/10/2002
342837-1551	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	10/218366	8/15/2002	6911439	6/28/2005
342837-1553	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	10/748089	12/29/2003	7005433	2/28/2006

Schedule A

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1582	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	11/033079	1/10/2005	7378529	5/27/2008
342837-1585	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	12/645154	12/22/2009	7973044	7/5/2011
342837-2400	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	09/489378	1/21/2000	6479492	11/12/2002
342837-2401	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	10/218445	8/15/2002	6903088	6/7/2005
342837-2416	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	11/145489	6/2/2005	7538215	5/26/2009
342837-1584	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	11/582293	10/16/2006	7741328	6/22/2010
342837-1552	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated BYVLA-4	United States of America	10/251442	9/20/2002	7049306	5/23/2006
342837-1586	HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	12/637719	12/14/2009	7968547	6/28/2011
342837-1550X	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	60/116923	1/22/1999		

Schedule A

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1551X	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	60/160999	10/21/1999		
342837-3899	HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 - US	United States of America	60/117760	1/29/1999		
342837-2080	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	60/168188	11/30/1999		
342837-1651	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	10/316189	12/11/2002	7452912	11/18/2008
342837-1650	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	09/489271	1/21/2000	6545003	4/8/2003
342837-1650X	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	60/116967	1/22/1999		
342837-1651X	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	60/117742	1/29/1999		
342837-2151	Alpha Aminocetic Acid Derivatives- Alpha 4 Beta 7 Receptor Antagonists	United States of America	10/147884	5/20/2002	6545160	4/8/2003



Schedule A

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-2150	Alpha-Aminoacetic Acid Derivatives - Alpha4Beta7 Receptor Antagonists	United States of America	09/514773	2/28/2000	6410781	6/25/2002
342837-2150X	Alpha Aminoacetic Acid Derivatives- Alpha 4 Beta 7 Receptor Antagonists	United States of America	60/122071	3/1/1999		
342837-1852	ALPHA AMINO ACID DERIVATIVES- INHIBITORS OF LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	10/936070	9/7/2004	7745454	6/29/2010
342837-1850	Alpha Amino Acid Derivatives -- Inhibitors of Leukocyte Adhesion Mediated by VLA-4	United States of America	09/910702	7/20/2001		
342837-1850X	Alpha Amino Acid Derivatives -- Inhibitors of Leukocyte Adhesion Mediated by VLA-4	United States of America	60/220132	7/21/2000		
342837-1950	3-(Heteroaryl)alanine Derivatives -- Inhibitors of Leukocyte Adhesion Mediated by VLA-4	United States of America	09/910466	7/19/2001	6794506	9/21/2004
342837-1952	3-(Heteroaryl) Alanine Derivatives- Inhibitors of Leukocyte Adhesion Mediated by VLA-4	United States of America	10/898576	7/23/2004	7365073	4/29/2008
342837-1953	3-(Heteroaryl)alanine Derivatives -- Inhibitors of Leukocyte Adhesion Mediated by VLA-4	United States of America	11/873358	10/16/2007		
342837-1950X	3-(Heteroaryl)alanine Derivatives -- Inhibitors of Leukocyte Adhesion Mediated by VLA-4	United States of America	60/220131	7/21/2000		
342837-1390	Heterocyclic Compounds Which Inhibit Leukocyte Adhesion Mediated By Alpha-4 Integrins	United States of America	11/527901	5/27/2003	7427628	9/23/2008

Schedule A

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1355	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	United States of America	10/494790	5/27/2003	7135477	11/14/2006
342837-1350	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	United States of America	10/447308	5/27/2003	7026328	4/11/2006
342837-4011	PYRIMIDINE HYDANTOIN ANALOGUES WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	11/118862	4/29/2005	7205310	4/17/2007
342837-4010	PYRIMIDINE HYDANTOIN ANALOGUES WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	60/566784	4/30/2004		
342837-4050	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	United States of America	60/722355	9/29/2005		
342837-4053	CARBAMATE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	12/759419	4/13/2010	8367688	2/5/2013
342837-4051	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	United States of America	11/541205	9/28/2006	7727996	6/1/2010
342837-4052	CARBAMATE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	12/579828	10/15/2009	8158642	4/17/2012
342837-4054	CARBAMATE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	13/416997	3/9/2012		

Schedule A

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-5002	PYRIMIDINYL AMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	12/352543	1/12/2009	7763632	7/27/2010
342837-5001	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	11/529815	9/28/2006	7511052	3/31/2009
342837-5000	Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4	United States of America	60/722358	9/29/2005		
342837-5052	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	12/505383	7/17/2009	7820687	10/26/2010
342837-5051	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	United States of America	11/679042	2/26/2007	7579466	8/25/2009
342837-5050	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	United States of America	60/777595	2/27/2006		
342837-5151	PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS	United States of America	12/768680	4/27/2010	8367836	2/5/2013
342837-5152	PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS	United States of America	13/730522	12/28/2012		
342837-5150	PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS	United States of America	61/172876	4/27/2009		
342837-1150	Substituted Phenylalanine type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	09/126095	7/30/1998	6492421	12/10/2002

Schedule A

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1150X	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	60/104599	7/31/1997		
		United States of America	08/920394	7/31/1998		

<b>MBHB Case No.</b>	<b>Application No. / Patent No.</b>	<b>Filing/Issued Date (mm/dd/yyyy)</b>	<b>Title</b>
05-052	USSN60/586,975	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-119	USSN60/683,509	05/20/2005	Imidazolone Phenylalanine Derivatives
05-051-PRO	USSN60/538573	01/23/2004	Polyethylene Glycol Conjugates Of Heterocycloalkyl Carboxamido Propanoic Acids
05-553	USSN60/697,726	07/08/2005	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
05-881	USSN60/802,349	05/22/2006	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-A	US8,138,272	03/20/2012	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-553-A	US8,268,935	09/18/2012	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
05-051-A	US7,595,318	09/29/2009	Polyethylene Glycol Conjugates Of Heterocycloalkyl Carboxamido Propanoic Acids
05-119-A	US8,030,328	10/04/2011	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-052-A-CON	US8,263,063	09/11/2012	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-A	US7,794,700	09/14/2010	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-A-CON2	13/606783	09/07/2012	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-A-CON3	13/831625	03/15/2013	Multimeric Vla-4 Antagonist Compressing Polymer Moieties

Schedule A

Country	Serial No.	Filing Date	Publication No.	Patent No.	Grant Date
United States	60/668404	04-Apr-05			
United States 01	11/887782	19-Mar-09	US2009-0176256	8124350	28-Feb-12
United States 02	13/242505	23-Sep-11	US2012-0195884		

## Schedule B

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0002-AU	2011323820	Oct-24-2011		METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IS sVCAM AND/OR sMAdCAM LEVELS
ELN-0002-CA	2,816,016	Oct-24-2011		METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IS sVCAM AND/OR sMAdCAM LEVELS
ELN-0002-EP	11838481.7	Oct-24-2011		METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IS sVCAM AND/OR sMAdCAM LEVELS
ELN-0002-JP	TBD	Oct-24-2011		METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IS sVCAM AND/OR sMAdCAM LEVELS
ELN-0002-WO	PCT/US2011/057519	Oct-24-2011		METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IS sVCAM AND/OR sMAdCAM LEVELS

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0003-CA	2,641,513	Feb-28-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0003-EP	07751683.9	Feb-28-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0003-EP-D1	13175987.0	Feb-28-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0003-JP	2008-557327	Feb-28-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0003-WO	PCT/US2007/004943	Feb-28-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0004-AU	2007224228	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-BR	PI 0708392-0	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-CA	2,644,110	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-CN	200780015815.5	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB

# Schedule B

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0004-CO	08.105.676	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-DZ	080582	Mar-02-2007	6107	METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-EA	200801933	Mar-02-2007	016626	METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-EC	PCT-08-8788	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-EG	1440/2008	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-EP	07751993.2	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-ID	W00200803172	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-IL	193775	Mar-02-2007	193775	METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-IN	8058/DELNP/2008	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-JP	2008-558307	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-JP-D1	2012-264135	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-KR	10-2008-7023464	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-MA	PV/31249	Mar-02-2007	30287	METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-MX	MX/a/2008/011176	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-MY	PI 20083409	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-NZ	570852	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-NZ-D1-	596359	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB



# Schedule B

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0004-NZ-D2	610405	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-PH	1-2008-501982	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-RS	P-391/2008	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-SG	200806732-4	Mar-02-2007	146063	METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-SG-D1	201101499-0	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-WO	PCT/US2007/005265	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-ZA	2008/07346	Mar-02-2007	2008/07346	METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0007-CA	2,066,738	Sep-13-1990	2,066,738	BLOOD-BRAIN BARRIER MODEL
ELN-0007-JP	2-513049	Sep-13-1990	3308526	BLOOD-BRAIN BARRIER MODEL
ELN-0007-JP-D1	2001-398632	Sep-13-1990		BLOOD-BRAIN BARRIER MODEL

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0008-AT	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-AU	16960/95	Jan-25-1995	703152	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-BE	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-CA1	2,182,013	Jan-25-1995	2,182,013	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-CA2	2,237,808	Nov-21-1996		THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
ELN-0008-CH	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4

Schedule B

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0008-CN	95191354.9	Jan-25-1995	ZL95191354.9	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-DE	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-DK	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-EP1	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-EP2	96943512.2	Nov-21-1996		THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
ELN-0008-EP-D1	06013916.9	Jan-25-1995	1759709	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-ES	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-FI	962958	Jan-25-1995	117509	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-FR	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-GB	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-GR	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-HU	P9602019	Jan-25-1995	220,799	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-IE	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-IT	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-JP1	7-519770	Jan-25-1995	4115517	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-JP2	9-519938	Nov-21-1996		THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
ELN-0008-JP-D1	2005-228930	Jan-25-1995		HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-JP-DIV	2008-153420	Nov-21-1996		THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
ELN-0008-JP-D2	2009-120421	Jan-25-1995		HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-JP-D3	2013-28635	Jan-25-1995		HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-JP-D4	2013-54628	Jan-25-1995		HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-KR	10-1996-0703987	Jan-25-1995	367948	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4

Schedule B

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0008-LU	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-MC	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-MX	962971	Jan-25-1995	198845	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-NL	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-NO	19963097	Jan-25-1995	319.867	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-NZ	279730	Jan-25-1995	279730	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-PL	P315634	Jan-25-1995	181827	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-PT	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-SE	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-WO01	PCT/US1995/001219	Jan-25-1995		HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-WO02	PCT/US1996/018807	Nov-21-1996		THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0009-AR	P030100608	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-AT	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009 AU	2003213231	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-AU-D1	2009201587	Feb-25-2003	2009201587	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-AU-D2	2012202155	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-BE	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-BG	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-BR	PI0307975-9	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION

# Schedule B

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0009-CA	2,477,178	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-CH	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-CL	357-2003	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-CN	03809138.0	Feb-25-2003	ZL03809138.0	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-CO	04095478	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-CY	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-CZ	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-DE	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-DK	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-EE	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-EG	191/2003	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-EP	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-EP-D1	10012870.1	Feb-25-2003		ADMISSION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-EP-D2	10012871.9	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-EP-D3	10012872.7	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-ES	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-FI	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-FR	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-GB	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION

# Schedule B

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0009-GR	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-HK	05105001.1	Feb-25-2003	1073997	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-HK-D1	11113804.6	Feb-25-2003		ADMISSION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-HK-D2	12101864.7	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-HK-D3	11107644.2	Feb-25-2003		ADMISSION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-HU	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-ID	W-00200402079	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-IE	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-IL	163725	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-IL-D1	203515	Feb-25-2003		COMPOSITION COMPRISING A - 4 - INTEGRIN FOR TREATING INFLAMMATION
ELN-0009-IN	2103/CHENP/2004	Feb-25-2003	229010	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-IN-D1	2196/CHENP/2008	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-IT	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-JP	2003-570787	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-JP-D1	2011-015696	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-KR	10-2004-7013609	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-LU	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-MC	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-MX	PA/a/2004/008267	Feb-25-2003	310728	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION

Schedule B

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0009-MY	PI20030650	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-NL	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-NO	20044054	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-NZ	535320	Feb-25-2003	535320	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-NZ-D1	566530	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009 -NZ-D2	579583	Feb-25-2003	579583	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-NZ-D3	591635	Feb-25-2003	591635	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-PE	195-03	Feb-27-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-PH	1-2004-501449	Feb-25-2003	1-2004-501449	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-PH-D1	1-2011-502301	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-PK	0161/03	Feb-26-2003	138459	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-PL	P-372306	Feb-25-2003	P-372306	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-PT	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-RU	2004128454	Feb-25-2003	235967	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-SA	03 24 0276	Sep-02-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-SE	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-SG	200404939-1	Feb-25-2003	107209 [WO 03/072040]	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-SI	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-SK	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION

# Schedule B

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0009-TH	080345	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-TR	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-TW	092103902	Feb-25-2003	1346558	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-TW-D1	100112502	May-03-2011		PHARMACEUTICAL COMPOSITION FOR DETERMINING EFFICACY OF CHRONIC TREATMENT OF INFLAMMATION
ELN-0009-UA	20040907793	Feb-25-2003	85537	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-UY	27688	Feb-27-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-VE	2003-000630	Apr-22-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-VN	1-2004-00960	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-WO	PCT/US2003/005421	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-ZA	2004/7406	Feb-25-2003	2004/7406	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0010-AR	P040100225	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-AU	2004207536	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-AU2	2004207535	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-AU-D1	2010212446	Jan-26-2004	2010212446	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS



## Schedule B

<b>A&amp;P File Reference</b>	<b>Application No.</b>	<b>Application Date</b>	<b>Registration No.</b>	<b>Title</b>
ELN-0010-AU2-D1	2010201472	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-AU-D2	2011201262	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-CA1	2,514,117	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-CA2	2,514,125	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-CL	0116-2004	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-CN	200480008089.0	Jan-26-2004	ZL200480008089.0	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-CO	05-084.319	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-EG	PCT 399/2005	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-EP	04705270.9	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-EP-D1	11008463.9	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-GC	GCC/P/2004/3259	Feb-28-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS

Schedule B

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0010-IL	169770	Jan-26-2004	169770	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-IN	1994/CHENP/2005	Jan-26-2004	229369	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-JP	2006-503001	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-JP2	2006-502997	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-JP-D1	2011-121017	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-KR	10-2005-7013695	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-KR-D1	10-2012-7024847	Jan-26-2004	1260497	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-MX	PA/a/2005/007843	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-MX 1	MX/A/2005/007823	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-MX-D1	MX/a/2008/007693	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-001-MX-D2	MX/a/2008/008267	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS

# Schedule B

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0010-MX-D3	MX/a/2010/001362	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-MY	PI 20040214	Feb-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-NO	20053920	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-PE	100			COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-PH	1-2005-501355	Jan-26-2004	1-2005-501355	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-PH-D1	1-2008-502081	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-PH-D2	1-2011-501872	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-PK	0040/2004	Jan-24-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-RU	2005126728	Jan-26-2004	2412721	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-SG	200504585-1	Jan-26-2004	P113988	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-SK	5064-2005	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS

Schedule B

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0010-TH	088245	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-TW	093101747	Jan-27-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-TW-D1	101146999	Jan-27-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-UA	200508278	Jan-26-2004	88604	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-UR	28170	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-VE	2004-000085	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-VN	1-2005-01185	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-WO	PCT/US2004/002039	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-ZA	2005/05869	Jan-26-2004	2005/05869	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0011-AR	P040100411	Feb-10-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-AU	2004210679	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-AUD1	2010202254	Feb-09-2004	2010202254	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-AUD2	2012202845	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF

# Schedule B

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0011-CA	2,515,444	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-CL	0224-2004	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-CN	200480009441.2	Feb-09-2004	ZL200480009441.2	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-CN-D1	201210292453.7	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-CO	05091313	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-EG	PCT 440/2005	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-EP	04709508.8	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-EP-D1	10005235.6	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-GC	GCC/P/2004/3212	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-HK	06111920.6	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-IL	170008	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-IN	2187/CHENP/2005	Feb-09-2004	252222	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-JP	2006-503453	Feb-09-2004	4728948	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-JP-D1	2010-277365	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-KR	10-2005-7014654	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-MX	PA/a/2005/008409	Feb-09-2004	302966	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-MX-D1	MX/a/2012/010160	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-MY	PI 20040377	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-NO	20054164	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-PE	149/2004	Feb-10-2004	5147	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-PH	1-2005-501425	Feb-09-2004	1-2005-501425	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-PK	0078/04	Feb-09-2004	138744	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-RU	2005128280	Feb-09-2004	2358763	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF

# Schedule B

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0011-SG	200505045-5	Feb-09-2004	114176	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-SK	PV 5067-2005	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-TH	088577	Feb-06-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-TW	093103043	Feb-10-2004	1367766	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-UA	200508632	Feb-09-2004	82685	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-UY	28184	Feb-10-2003		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-VE	2004-000165	Feb-04-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-VN	1-2005-01248	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-WO	PCT/US2004/003873	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-ZA	2005/06159	Feb-09-2004	2005/06159	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0012-AR	P050100431	Feb-04-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-AU	2005213324	Feb-03-2005	2005213324	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-AU-D1	2011211351	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-BR	PI0507451.7	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-CA	2,555,365	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-CL	203-2005	Feb-02-2005	45,773	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-CN	200580012148.6	Feb-03-2005	ZL200580012148.6	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-EA	200601433	Feb-03-2005	009873	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-EP	05712339.0	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-EP-D1	11005763.5	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-GC	GCC/P/2005/4271	Feb-06-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE

Schedule B

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0012-HK	07104930.8	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-ID	W-00200602188	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-IL	177201	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-IN	3236/CHENP/2006	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-JP	2006-552178	Feb-03-2005	4996261	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-KR	10-2006-7018079	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-MX	PA/a/2006/008746	Feb-03-2005	286237	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-MY	PI 20050455	Feb-04-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-NO	2006 3951	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-NZ	548851	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-NZ-D1	584288	Feb-03-2005	584288	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-NZ-D2	595379	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-PE	129.2005	Feb-04-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-PH	1-2006-501514	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-PK	0068/05	Feb-02-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-TH	097446	Feb-15-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-TW	094103833	Feb-05-2005	I375563	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-UY	28741	Feb-04-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-VE	2005-000205	Feb-04-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-WO	PCT/US2005/002860	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-ZA	2006/06557	Feb-03-2005	2006/06557	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE



# Schedule B

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0013 AU	2005232571	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-AU 2	2005231467	Apr-01-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-AU-D1	2011213878	Mar-30-2005	2011213878	STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-CA 2	2,561,164	Apr-01-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-CA	2,561,364	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-CL	742-2005	Mar-31-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-EP	05768245.2	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013 EP2	05763852.0	Apr-01-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-GC	GCC/P/2005/4496	Apr-02-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-HK	07106887.6	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013 HK2	07110080.3	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-IL	178302	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-JP	2007-506536	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-JP 2	2007-506344	Apr-01-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-JP-D1	2013-080823	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-MY	PI 20051380	Mar-29-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-NO	2006 4979	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-NZ	550040	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-NZ-D1	580057	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-NZ-D2	594476	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-TH	099245	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-TW	094110385	Mar-31-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-UY	28838	Apr-01-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-WO	PCT/US2005/010848	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013 WO2	PCT/US2005/011307	Apr-01-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent Number	Grant Date
342837-1456	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Argentina	P980103779	7/31/1998		

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1462	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Australia	85849/98	7/31/1998	740681	2/21/2002
342837-1463	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Brazil	PI9811598-7	7/31/1998		
342837-1465	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Canada	2290745	7/31/1998		
342837-1484	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	China P.R.	98807770.1	7/31/1998	ZL988077 70.01	8/27/2003
342837-1479	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Germany	69824007.3	7/31/1998	EP100005 1	5/19/2004
342837-1466	CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	European Patent Office	98937052.3	7/31/1998	1000051	5/19/2004
342837-1485	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	European Patent Office	04011786.3	7/31/1998	145532	9/1/2004
342837-1480	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Spain	98937052.3	7/31/1998	1000051	5/19/2004
342837-1481	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	France	98937052.3	7/31/1998	100051	5/19/2004
342837-1482	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United Kingdom	98937052.3	7/31/1998	1000051	5/19/2004

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1467	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Hong Kong	00105670.6	7/31/1998	1000051	
342837-1486	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Hong Kong	05100583.8	7/31/1998	1067131A	4/1/2005
342837-1468	CARBAMYL COMPUONDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Hungary	P0002035	7/31/1998		
342837-1483	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Ireland	98937052.3	7/31/1998	EP1000051	5/19/2004
342837-1469	CARBAMYL COMPUONDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Israel	133636	7/31/1998		
342837-1490	ALPHA-9 INTEGRIN ANTAGONISTS AND ANTI-INFLAMMATORY COMPOSITIONS THEROF	Japan	11-511273	7/31/1998		
342837-1470	CARBAMYL COMPUONDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Japan	2000-505149	7/31/1998	4431717	1/8/2010
342837-1491	CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADEHSION MEDIATED BY VLA-4	Japan	2009-185319	8/7/2009		
342837-1478	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	South Korea	10-2000-7000952	7/31/1998	639055	10/20/2006
342837-1471	CARBAMYL COMPUONDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Mexico	000673	7/31/1998	225022	12/15/2004

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1473	CARBAMYL COMPUONDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Norway	20000413	7/31/1998		
342837-1472	CARBAMYL COMPUONDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	New Zealand	502578	7/31/1998		
342837-1455	CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	P.C.T.	PCT/US1998/01 5324	7/31/1998		
342837-1460	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Philippines	1-1998-001943	7/31/1998	1-1998-01943	10/18/2006
342837-1459	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Pakistan	790/98	7/30/1998		
342837-1474	CARBAMYL COMPUONDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Poland	P-338521	7/31/1998		
342837-1475	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Russian Federation	2000104850	7/31/1998	2220964	1/10/2004
342837-1476	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Singapore	9906195-4	7/31/1998	69767	3/22/2002
342837-1489	ALPHA-9 INTEGRIN ANTAGONISTS AND ANTI-INFLAMMATORY COMPOSITIONS THEROF	P.C.T.	PCT/US1998/01 5958	7/31/1998		
342837-1457	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Venezuela	1998-001683	7/30/1998		

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1461	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	South Africa	98/6830	7/30/1998		
342837-1477	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	South Africa				
342837-1555	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Argentina	P000100287	1/24/2000		
342837-2403	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Argentina	P000100286	1/24/2000	AR 033643	11/24/2010
342837-1561	Acyl Derivatives which Treat VLA-4 Related Disorders	Australia	34724/00	1/21/2000	773538	9/9/2004
342837-1562	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	Brazil	0007663-5	1/21/2000		
342837-2409	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Canada	2359113	1/21/2000		
342837-1563	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Canada	2359115	1/21/2000	2359115	6/21/2011
342837-1587	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	Switzerland	00913245.7	1/21/2000	1144388	1/13/2010
342837-2404	COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Chile	141-2000	1/24/2000		
342837-1556	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Chile	140-2000	1/24/2000	48387	4/19/2012
342837-1564	Acyl Derivatives Which Treat VLA-4 Related Disorders	China P.R.	00804078.8	1/21/2000	ZL008040 78.8	9/28/2005

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-2410	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	China P.R.	00804498.8	1/21/2000		
342837-1565	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Czech Republic	PV2001-2361	1/21/2000		
342837-1588	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	Germany	00913245.7	1/21/2000	1144388	1/13/2010
342837-1589	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	Denmark	00913245.7	1/21/2000	1144388	1/13/2010
342837-1566	HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Eurasian Pat. Convention	200100797	1/21/2000	006301	10/27/2005
342837-1567	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	European Patent Office	00913245.7	1/21/2000	1144388	1/13/2010
342837-2411	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	European Patent Office	00904487.6	1/21/2000	1144384	10/31/2007
342837-2417	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United Kingdom	00904487.6	1/21/2000	1144384	10/31/2007
342837-1590	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	Spain	00913245.7	1/21/2000	1144388	1/13/2010
342837-1591	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	France	00913245.7	1/21/2000	1144388	1/13/2010
342837-1592	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	United Kingdom	00913245.7	1/21/2000	1144388	1/13/2010
342837-1579	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Hong Kong	02106386.7	1/21/2000		
342837-1580	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	Hong Kong	02107038.7	1/21/2000	1046132	5/4/2006

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-2414	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Hong Kong	02106386.7	1/21/2000		
342837-1568	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Hungary	P0201213	1/21/2000		
342837-1593	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	Ireland	00913245.7	1/21/2000	1144388	1/13/2010
342837-2418	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Ireland	00904487.6	1/21/2000	1144384	10/31/2007
342837-1569	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	Israel	143929	1/21/2000	143929	6/21/2008
342837-1570	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	India	IN/PCT/2001/00984/CHE	1/21/2000		
342837-2412	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Japan	2000-594785	1/21/2000		
342837-1571	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	South Korea	2001-7009075	1/21/2000	711840	4/19/2007
342837-1573	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	Mexico	PA/a/2001/007335	1/21/2000	244336	3/22/2007
342837-2413	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Mexico	PA/a/2001/007396	1/21/2000	223125	9/29/2004
342837-2415	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Mexico	PA/a/2004/005706	1/21/2000	254447	2/11/2008
342837-1594	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	Netherlands	00913245.7	1/21/2000	1144388	1/13/2010
342837-1575	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Norway	20013600	1/21/2000	323373	4/16/2007

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1574	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	New Zealand	512563	1/21/2000		
342837-1581	Acyl Derivatives Which Treat VLA-4 Related Disorders	New Zealand	529822	1/21/2000	529822	3/9/2006
342837-1554	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	P.C.T.	PCT/US2000/001686	1/21/2000		
342837-2402	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	P.C.T.	PCT/US2000/001540	1/21/2000		
342837-1557	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Philippines	1-2000-00159	1/21/2000	1-2000-00159	5/26/2005
342837-2405	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Philippines	1-2000-00160	1/21/2000		
342837-1558	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Pakistan	0047/2000	1/22/2000	140939	12/16/2011
342837-2406	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Pakistan	48/2000	1/22/2000		
342837-1576	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Poland	P-350050	1/21/2000		
342837-1583	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Russian Federation	200100797	1/21/2000	006301	10/27/2005
342837-1595	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	Sweden	00913245.7	1/21/2000	1144388	1/13/2010



Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1577	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Singapore	200104173-0	1/21/2000		
342837-1559	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Taiwan	089101088	1/24/2000	I239954	9/21/2005
342837-2407	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Taiwan	89101087	1/24/2000		
342837-1560	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Venezuela	2000-000165	1/24/2000		
342837-2408	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Venezuela	2000-000163	1/24/2000		
342837-1578	ACYL DERIVATIVES WHICH TREAT VLA 4 RELATED DISORDERS	South Africa	2001/05314	1/21/2000	2001/05314	6/25/2003
342837-1578	ACYL DERIVATIVES WHICH TREAT VLA 4 RELATED DISORDERS	South Africa	2001/05314	1/21/2000	2001/05314	6/25/2003
342837-1653	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Argentina	P000100266	1/21/2000		
342837-1659	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Australia	25135/00	1/21/2000	769741	5/27/2004

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1660	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Canada	2359112	1/21/2000		
342837-1654	Fused Ring Heteroaryl and Heterocyclic Compounds Which Inhibit Leukocyte Adhesion by VLA-4	Chile	128-2000	1/21/2000		
342837-1661	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	China P.R.	00802933.4	1/21/2000		
342837-1662	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	European Patent Office	00903379.6	1/21/2000		
342837-1668	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Hong Kong	02105462.6	1/21/2000		
342837-1663	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Israel	143928	1/21/2000	143928	5/12/2007
342837-1665	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Mexico	PA/a/2001/007 330	1/21/2000	223926	11/3/2004

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1666	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	New Zealand	512565	1/21/2000	512565	3/29/2004
342837-1669	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	New Zealand	528904	1/21/2000		
342837-1652	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	P.C.T.	PCT/US2000/00 1536	1/21/2000		
342837-1655	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Philippines	1-2000-00158	1/21/2000		
342837-1656	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Pakistan	0045/2000	1/21/2000		
342837-1657	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Taiwan	089100997	1/21/2000	NI-203589	6/21/2004
342837-1658	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Venezuela	2000-000151	1/21/2000		

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1667	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	South Africa	20015312	1/21/2000	2001/05312	12/24/2002
342837-2154	PHA-AMINOACETIC ACID DERIVATIVES USEFUL AS ALPHA 4 BETA 7-RECEPTOR ANTAGONISTS	Canada	2361162	2/28/2000		
342837-2157	Alpha Aminoacetic Acid Derivatives- Alpha 4 Beta 7 Receptor Antagonists	Germany	00910364.9	2/28/2000	60009883-4	4/14/2004
342837-2155	ALPHA-AMINOACETIC ACID DERIVATIVES USEFUL AS ALPHA 4 BETA 7 - RECEPTOR ANTAGONISTS	European Patent Office	00910364.9	2/28/2000	1161416	4/14/2004
342837-2156	Alpha Aminoacetic Acid Derivatives- Alpha 4 Beta 7 Receptor Antagonists	France	00910364.9	2/28/2000	1161416	4/14/2004
342837-2158	Alpha Aminoacetic Acid Derivatives- Alpha 4 Beta 7 Receptor Antagonists	United Kingdom	00910364.9	2/28/2000	1161416	4/14/2004
342837-2159	Alpha Aminoacetic Acid Derivatives- Alpha 4 Beta 7 Receptor Antagonists	Ireland	00910364.9	2/28/2000	1161416	4/14/2004
342837-2153	Alpha Aminoacetic Acid Derivatives- Alpha 4 Beta 7 Receptor Antagonists	Japan	2000-602202	2/28/2000		
342837-2152	Alpha-Aminoacetic Acid Derivatives Useful As Alpha 4 Beta 7 - Receptor Antagonists	P.C.T.	PCT/US2000/004960	2/28/2000		
342837-1572	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	Japan	2000-594788	1/21/2000	4754693	6/3/2011
342837-1596	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Japan	2011-11456	1/21/2000		

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1851	Alpha Amino Acid Derivatives -- Inhibitors of Leukocyte Adhesion Mediated by VLA-4	P.C.T.	PCT/US2001/02 3075	7/20/2001		
342837-1951	3-(Heteroaryl)alanine Derivatives -- Inhibitors of Leukocyte Adhesion Mediated by VLA-4	P.C.T.	PCT/US2001/02 3097	7/20/2001		
342837-1378	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	United Arab Emirates	471/2004	5/27/2003		
342837-1600	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Armenia	200401562	5/27/2003	008256	4/27/2007
342837-1353	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Argentina	P030104212	11/14/2003		
342837-1357	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Australia	2003240823	5/27/2003	2003240823	5/21/2009
342837-1601	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Azerbaijan	200401562	5/27/2003	008256	4/27/2007
342837-1358	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Brazil	PI0308881-2	5/27/2003		
342837-1602	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Belarus	200401562	5/27/2003	008256	4/27/2007

Schedule B

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent Number	Grant Date
342837-1359	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Canada	2481926	5/27/2003	2481926	4/24/2012
342837-1388	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Switzerland	03731419.2	5/27/2003	1507775	12/31/2008
342837-1360	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	China P.R.	03811548.4	5/27/2003	ZL03811548.4	5/9/2007
342837-1381	N-[2-N', N'-DIETHYLAMINOSULFONYLPHENLYPYRIMIDIN-4-YL] P-CARBOMYLOXY-PHENYLALANINE DERIVATIVE COMPOUNDS	Colombia	03-103.979A	11/25/2003	29059	8/28/2009
342837-1354	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Colombia	03-103.979	11/25/2003	29022	8/28/2009
342837-1382	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Germany	03731419.2	5/27/2003	60325583.3-08	12/31/2008
342837-1389	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Denmark	03731419.2	5/27/2003	1507775	12/31/2008
342837-1371	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Eurasian Pat. Convention	200401562	5/27/2003	008256	1/15/2007

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1376	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Ecuador	04-5425-PCT	5/27/2003	PI 2011-2058	1/20/2011
342837-1379	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Egypt	120/2004	5/27/2003		
342837-1375	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	European Patent Office	03731419.2	5/27/2003	1507775	12/31/2008
342837-1383	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Spain	03731419.2	5/27/2003	1507775	12/31/2008
342837-1384	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	France	03731419.2	5/27/2003	1507775	12/31/2008
342837-1385	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	United Kingdom	03731419.2	5/27/2003	1507775	12/31/2008
342837-1380	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Hong Kong	05106028.8	5/27/2003	1072608	8/14/2009
342837-1363	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Indonesia	W-00200402607	5/27/2003	ID0019145	4/18/2007

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1386	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Ireland	03731419.2	5/27/2003	1507775	12/31/2008
342837-1364	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Israel	164225	5/27/2003	164225	3/1/2011
342837-1362	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	India	1535/KOLNP/2004	5/27/2003	215531	2/27/2008
342837-1387	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Italy	03731419.2	5/27/2003	1507775	12/31/2008
342837-1365	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Japan	2004-507466	5/27/2003	4469715	3/5/2010
342837-1603	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Kyrgyzstan	200401562	5/27/2003	008256	4/27/2007
342837-1366	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	South Korea	2004-7018173	5/27/2003	10-0978832	8/24/2010
342837-1604	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Kazakhstan	200401562	5/27/2003	008256	4/27/2007



Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1391	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Luxembourg	03731419.2	5/27/2003	1507775	12/31/2008
342837-1605	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Moldova	200401562	5/27/2003	008256	4/27/2007
342837-1367	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Mexico	PA/a/2004/010 995	5/27/2003	268526	7/22/2009
342837-1392	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Netherlands	03731419.2	5/27/2003	1507775	12/31/2008
342837-1369	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Norway	20043900	5/27/2003	329933	1/24/2011
342837-1368	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	New Zealand	535504	5/27/2003	535504	3/9/2006
342837-1351	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	P.C.T.	PCT/US2003/01 6804	5/27/2003		
342837-1370	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Philippines	1-2004-501523	5/27/2003	1-2004-501523	6/30/2009

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1606	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Russian Federation	200401562	5/27/2003	008256	4/27/2007
342837-1372	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Singapore	200405708-9	5/27/2003	106956	12/29/2006
342837-1607	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Tajikistan	200401562	5/27/2003	008256	4/27/2007
342837-1608	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Turkmenistan	200401562	5/27/2003	008256	4/27/2007
342837-1352	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Taiwan	092114183	5/26/2003	1281470	5/21/2007
342837-1377	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Ukraine	20041008397	5/27/2003	76339	7/17/2006
342837-1374	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Vietnam	1-2004-00949	5/27/2003	6926	3/17/2008
342837-1373	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	South Africa	2004/7590	5/27/2003	2004/7590	10/25/2006

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-4012	PYRIMIDINE HYDANTOIN ANALOGUES WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	P.C.T.	PCT/US2005/014885	4/29/2005		
342837-4061	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Australia	2006297180	9/28/2006		
342837-4062	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Brazil	PI0616643-1	9/28/2006		
342837-4064	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	China P.R.	200680035707.X	9/28/2006		
342837-4065	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	European Patent Office	06804266.2	9/28/2006	1940827	3/16/2011
342837-4072	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Switzerland	06804266.2	9/28/2006	1940827	3/16/2011
342837-4073	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Germany	06804266.2	9/28/2006	1940827	3/16/2011
342837-4074	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	France	06804266.2	9/28/2006	1940827	3/16/2011
342837-4075	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	United Kingdom	06804266.2	9/28/2006	1940827	3/16/2011
342837-4076	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Ireland	06804266.2	9/28/2006	1940827	3/16/2011

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-4071	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Hong Kong	08112826.7	9/28/2006		
342837-4066	CARBAMATE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	India	800/KOLNP/20 08	9/28/2006		
342837-4067	CARBAMATE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Japan	2008-533682	9/28/2006	5081828	9/7/2012
342837-4077	CARBAMATE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Japan	2012-16870	9/28/2006		
342837-4068	CARBAMATE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Mexico	MX/a/2008/004 136	9/28/2006		
342837-4069	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	New Zealand	567296	9/28/2006		
342837-4063	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Canada	2624524	9/28/2006		
342837-4060	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	P.C.T.	PCT/US2006/03 8113	9/28/2006		
342837-5011	PYRIMIDINYL AMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Australia	2006297220	9/28/2006	20062972 20	11/22/2012
342837-5012	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Brazil	PI0616887-3	9/28/2006		

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-5013	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Canada	2624450	9/28/2006		
342837-5014	PYRIMIDINYL AMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	China P.R.	200680035654.1	9/28/2006	ZL 20068003 5654.1	7/27/2011
342837-5015	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Colombia	08030304	9/28/2006		
342837-5016	PYRIMIDINYL AMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Eurasian Pat. Convention	200800975	9/28/2006	015388	8/30/2011
342837-5017	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	European Patent Office	06804253.0	9/28/2006	1940826	12/29/2010
342837-5030	PYRIMIDINYL AMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	European Patent Office				
342837-5031	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Switzerland	06804253.0	9/28/2006	1940826	12/29/2010
342837-5032	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Germany	06804253.0	9/28/2006	60200601 9296.7	12/29/2010
342837-5033	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Denmark	06804253.0	9/28/2006	1940826	12/29/2010
342837-5034	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	France	06804253.0	9/28/2006	1940826	12/29/2010

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-5035	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	United Kingdom	06804253.0	9/28/2006	1940826	12/29/2010
342837-5036	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Ireland	06804253.0	9/28/2006	1940826	12/29/2010
342837-5037	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Sweden	06804253.0	9/28/2006	1940826	12/29/2010
342837-5028	Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4	Hong Kong	08113271.5	9/28/2006		
342837-5018	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Indonesia	W00200800840	9/28/2006		
342837-5019	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Israel	190084	9/28/2006		
342837-5020	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	India	1046/KOLNP/2008	9/28/2006		
342837-5021	PYRIMIDINYL AMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Japan	2008-533649	9/28/2006	5101512	10/5/2012
342837-5022	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	South Korea	10-2008-7010301	9/28/2006		
342837-5023	PYRIMIDINYL AMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Mexico	MX/a/2008/004030	9/28/2006	288343	1/25/2011

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-5024	PYRIMIDINYL AMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Norway	20082002	9/28/2006		
342837-5025	Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4	New Zealand	567270	9/28/2006	567270	10/10/2011
342837-5010	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	P.C.T.	PCT/US2006/03 8009	9/28/2006		
342837-5026	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Philippines	1-2008-500753	9/28/2006		
342837-5027	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	South Africa	2008/03280	9/28/2006	2008/032 80	11/29/2009
342837-5029	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	South Africa	2009/06610	9/28/2006	2009/066 10	5/25/2011
342837-5061	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Argentina	070100812	2/27/2007		
342837-5063	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Australia	2007220068	2/26/2007		
342837-5085	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Australia	2012261691	2/26/2007		

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-5064	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Brazil	0708331-9	2/26/2007		
342837-5065	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Canada	2643838	2/26/2007		
342837-5066	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	China P.R.	200780006583.7	2/26/2007	ZL 200780006583.7	7/18/2012
342837-5075	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Colombia	08.096.101	2/26/2007		
342837-5076	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Eurasian Pat. Convention	200801906	2/26/2007	017110	9/28/2012
342837-5086	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Armenia				
342837-5087	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Azerbaijan	200801906	2/26/2007	017110	9/28/2012
342837-5088	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Belarus	200801906	2/26/2007	017110	9/28/2012



Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-5089	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Kazakhstan	200801906	2/26/2007	017110	9/28/2012
342837-5090	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Kyrgyzstan	200801906	2/26/2007	017110	9/28/2012
342837-5091	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Moldova	200801906	2/26/2007	017110	9/28/2012
342837-5092	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Russian Federation	200801906	2/26/2007	017110	9/28/2012
342837-5093	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Tajikistan	200801906	2/26/2007	017110	9/28/2012
342837-5094	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Turkmenistan	200801906	2/26/2007	017110	9/28/2012
342837-5077	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Ecuador	SP-08-8701	2/26/2007		
342837-5078	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Egypt	1394/2008	8/18/2008		

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-5067	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	European Patent Office	07757498.6	2/26/2007		
342837-5084	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Hong Kong	09104919.1	2/26/2007		
342837-5068	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Israel	193425	2/26/2007		
342837-5069	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	India	3409/KOLNP/2008	2/26/2007		
342837-5079	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Japan	2008-556582	2/26/2007	5135235	11/16/2012
342837-5070	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	South Korea	10-2008-7023333	2/26/2007		
342837-5081	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Morocco	31231	2/26/2007	30318	4/1/2009
342837-5071	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Mexico	MX/a/2008/010988	2/26/2007	286803	5/20/2011

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-5080	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Malaysia	PI 20083293	2/26/2007		
342837-5072	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Norway	20083743	2/26/2007		
342837-5073	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	New Zealand	570679	2/26/2007		
342837-5060	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	P.C.T.	PCT/US2007/06 2824	2/26/2007		
342837-5083	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Philippines	1-2008-501917	2/26/2007		
342837-5082	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Singapore	200806100-4	2/26/2007	145322	3/15/2011
342837-5062	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Taiwan	096106544	2/26/2007		
342837-5074	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	South Africa	2008/07188	2/26/2007	2008/071 88	1/27/2010
342837-5160	PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS	P.C.T.	PCT/US2010/03 2632	4/27/2010		

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-5161	PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS	Australia	2010241742	4/27/2010		
342837-5162	PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS	Brazil	PI1015259-8	4/27/2010		
342837-5163	PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS	Canada	2760151	4/27/2010		
342837-5164	PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS	China P.R.	201080027375.7	4/27/2010		
342837-5165	PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS	European Patent Office	10719684.2	4/27/2010		
342837-5166	PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS	India	4416/KOLNP/2011	4/27/2010		
342837-5167	PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS	Israel	215956	4/27/2010		
342837-5168	PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS	Japan	2012-507475	4/27/2010		
342837-5169	PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS	Mexico	MX/a/2011/011326	4/27/2010		
342837-5170	PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS	Singapore	201107840-9	4/27/2010		
342837-1152	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Argentina	P980103778	7/30/1998		
342837-1158	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Australia	86611/98	7/30/1998	756696	5/8/2003
342837-1159	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Brazil	PI9812114-6	7/30/1998		

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1160	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Canada	2290747	7/30/1998		
342837-1161	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	China P.R.	98807753.1	7/30/1998	ZL98807753.1	1/7/2004
342837-1162	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	European Patent Office	98937990.4	7/30/1998		
342837-1163	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Hungary	P0004259	7/30/1998		
342837-1173	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Hong Kong	00105671.5	7/30/1998		
342837-1164	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Israel	133640	7/30/1998		
342837-1165	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Japan	2000-505186	7/30/1998		
342837-1172	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	South Korea	10-2000-7000991	7/30/1998		

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1166	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Mexico	000711	7/30/1998		
342837-1168	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Norway	20000450	7/30/1998		
342837-1167	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	New Zealand	502582	7/30/1998	502582	11/4/2002
342837-1151	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	P.C.T.	PCT/US1998/015313	7/30/1998		
342837-1153	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Philippines	1998-001905	7/24/1998	1-1998-01905	3/24/2005
342837-1154	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Pakistan	0792/98	7/30/1998		
342837-1169	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Poland	P-338423	7/30/1998		
342837-1174	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Poland	P-375244	7/30/1998		

Schedule B

<b>F&amp;L Docket No.</b>	<b>Title</b>	<b>Country</b>	<b>Application Number</b>	<b>Appl Date</b>	<b>Patent Number</b>	<b>Grant Date</b>
342837-1170	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Russian Federation	2000104853	7/30/1998		
342837-1171	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Singapore	9906211-9	7/30/1998	69778	4/10/2002
342837-1155	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Taiwan	087112638	7/31/1998	NI-178968	6/1/2003
342837-1156	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Venezuela	1998-001702	7/31/1998		
342837-1157	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	South Africa	98/6827	7/30/1998	98/6827	7/26/2000

<b>MBHB Case No.</b>	<b>Application No. / Patent No.</b>	<b>Filing/Issued Date (mm/dd/yyyy)</b>	<b>Title</b>
05-119-WO-KR	KR 10-2007-7029811	12/20/2007	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-119-WO	PCT/US2006//19708	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-051-B1	CA2554188	01/24/2005	Polyethylene Glycol Conjugates Of Heterocycloalkyl Carboxamido Propanoic Acids
05-051-B2	EP05712086.7	01/24/5005	Polyethylene Glycol Conjugates Of Heterocycloalkyl Carboxamido Propanoic Acids
05-051-B3	JP2006-551442	01/24/2005	Polyethylene Glycol Conjugates Of Heterocycloalkyl Carboxamido Propanoic Acids
05-051-B	PCT/US2005/002478	01/24/2005	Polyethylene Glycol Conjugates Of Heterocycloalkyl Carboxamido Propanoic Acids
05-553-WO	PCT/US2006/26292	07/07/2006	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds

Schedule B

<b>MBHB Case No.</b>	<b>Application No. / Patent No.</b>	<b>Filing/Issued Date (mm/dd/yyyy)</b>	<b>Title</b>
05-881-WO-AU	AU2007253717	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-BR	BR PI07I2013-3	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-CA	CA2651500	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-CN	CN2007800278I 0.4	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-CO	C008.135.138	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-ES	EA20087056I	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-EP	EP07762290.0	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-CN-HK	HK091082I8.0	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-ID	ID W-00200803766	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-IL	ILI95I47	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-IN	IN458I /KOLNP/2008	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-JP	JP2009-5I2263	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-KR	KR I 0-2008-7030834	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-MX	MX/a/2008/0I4520	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-NO	N0200853IO	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-NZ	NZ5728I6	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-PH	PH I-2008-502500	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-SG	SG2008 084668-3	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-C	TW0966I8233	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO	PCT/US2007/069464	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds



Schedule B

<b>MBHB Case No.</b>	<b>Application No. / Patent No.</b>	<b>Filing/Issued Date (mm/dd/yyyy)</b>	<b>Title</b>
05-881-ZA-DIV	ZA2010/08198	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-ZA	ZA2008/09564	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-553-WO-IL	IL188194	12/17/2007	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
05-553-WO-IN	IN5075/KOLNP/2007	12/28/2007	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
05-553-WO-JP	JP2008-520379	01/07/2008	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
05-553-WO-KR	KR2008-7002982	02/04/2008	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
05-553-WO-MX	MX MX/a/2008/000291 Patent No. 303295	07/07/2006 09/11/2012	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
05-553-WO-NZ	NZ564836 Patent No. 564836	07/07/2006 02/07/2012	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
05-553-SG-DIV	SG201004810-6	07/07/2006	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
05-553-WO-SG	SG2007-18828-7	07/07/2006	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
05-553-WO-ZA	ZA2007/11116 Patent No. 2007/11116	07/07/2006 09/25/2008	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
05-553-WO-AU	AU2006269382	07/07/2006	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
05-553-WO-BR	BR PI0612407-0	07/07/2006	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
05-553-WO-CA	CA2614200	07/07/2006	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
05-553-WO-CN	CN200680031902.5	07/07/2006	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
05-553-WO-CO	C008012301 Patent No. 50046	02/07/2008 08/24/2012	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
05-553-WO-EP	EP06786449.6	07/07/2006	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
05-553-CN-HK	HK09108998.6	09/29/2009	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
05-119-WO-AU	A U2006251620	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-119-WO-BR	BR PI0611285-4	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists

Schedule B

<b>MBHB Case No.</b>	<b>Application No. / Patent No.</b>	<b>Filing/Issued Date (mm/dd/yyyy)</b>	<b>Title</b>
05-119-WO-CA	CA2608073	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-119-WO-CN	CN20068002461 0.	01/04/2008	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-119-WO-EP	EP06770821.4	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-119-CN-HK	HK08113753.2	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-119-WO-IN	IN4506/KOLNP/2007	11/22/2007	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-119-WO-JP	JP2008-512589	11/19/2007	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
	Patent No. 5231215	03/29/2013	
05-119-WO-MX	MX/a/2007/014267	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
	Patent No. 293500	12/12/2011	
05-119-WO-NZ	NZ563577	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-119-SG-DIV	SG2010 03303-3	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-119-WO-SG	SG2007-17692-8	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-119-WO-ZA	ZA2007/09717	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
	Patent No. 2007/09717	10/29/2008	
05-052-AR	AR P050102848	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B7-AM	AM012433	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B1	AU2005265316	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
	Patent No. 2005265316	05/17/2012	
05-052- B7-AZ	AZ012433	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B2	BR PI0513143-0	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052- B7-BY	BY012433	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-WO-CA	CA2573245	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-C	CL1725-05	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B4	CN200580029853.7	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
	Patent No. 200580029853	03/28/2012	
05-052-B7	EA012433	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B9	EC SP-07-7231	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B8	EG16/2007	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B6-DIV2	EP10179711.6	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B6-DIV1	EP10179709.0	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B6-DIV3	EP10180274.2	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B6	EP05770402.5	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties

Schedule B

<b>MBHB Case No.</b>	<b>Application No. / Patent No.</b>	<b>Filing/Issued Date (mm/dd/yyyy)</b>	<b>Title</b>
05-052-B5	HK07109071.6	08/21/2007	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B6-DIV2	HKIII09881.0	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B5-2	HK08102319.2	02/29/2008	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
	Patent No. 1111674	12/28/2012	
05-052-B11	ID W-00200700049	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B12	ILI80558	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B10	IN131/KOLNP/2007	01/10/2007	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B10-DIV	IN4960/KOLNP/2011	12/09/2011	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B13	JP2007-520561	01/05/2007	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052- B7-KG	KGOI2433	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B20	KR10-2007-70031 08	02/08/2007	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052- B7-KZ	KZOI2433	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B15	MA29658	02/05/2007	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
	Patent No. 28786	08/1/2007	
05-052- B7-MD	MDOI2433	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B14	MX/a/2007/000228	01/08/2007	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
	Patent No. 292893	12/01/2011	
05-052-B17	N020070216	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B16-DIV	NZ588839	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
	Patent No. 588839	01/04/2013	
05-052-B16	NZ552521	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-D-DIV	PE260.12009	07/19/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-D	PE835/2005	07/19/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
	Patent No. 5410	09/10/2009	
05-052-B18	PH 1-2005-500057	01/05/2007	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B7-RU	RUOI2433	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B21	SG2007001407	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
	Patent No. I28947	12/31/2008	
05-052-B7-TJ	TJOI2433	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052- B7-TM	TMOI2433	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-G	TW094123303	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-E	VE2005-001467	07/21/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties

Schedule B

<b>MBHB Case No.</b>	<b>Application No. / Patent No.</b>	<b>Filing/Issued Date (mm/dd/yyyy)</b>	<b>Title</b>
05-052-B19	ZA2007/000238	07/08/2005	Multimeric V1a-4 Antagonist Compressing Polymer Moieties
	Patent No. 2007/00238	07/30/2008	
05-052-B	PCT/US05/24369	07/08/2005	Multimeric V1a-4 Antagonist Compressing Polymer Moieties

Schedule B

Country	Serial No.	Filing Date	Publication No.	Patent No.	Grant Date
Australia	2006231511	04-Apr-06		2006231511	31-May-12
Australia 01	2012202823	04-Apr-06			
Canada	2603481	04-Apr-06			
China	200680019422.7	04-Apr-06	CN 101351710A		
Europe	06749243.9	04-Apr-06	1872136		
Europe 01	13158951.7	04-Apr-06			
Hong Kong	08107142.4	04-Apr-06	1112059A		
India	4955/CHENP/2007	04-Apr-06			
Israel	186431	04-Apr-06		186431	30-Jun-12
Japan	2008-505451	04-Apr-06			
Japan 01	2011-213503	04-Apr-06			
New Zealand	562784	04-Apr-06		562784	06-Nov-10
PCT	PCT/US2006/012493	04-Apr-06	WO2006/107962		
Singapore	200716554-1	04-Apr-06		136340	30-Apr-10